CombiMatrix Corporation, a molecular diagnostics company specializing in DNA-based testing services for developmental disorders and cancer diagnostics, has been selected by American Pathology Partners (AP2) to provide its chromosomal microarray analysis (CMA) testing for miscarriage analysis to AP2 patients. American Pathology Partners is creating a nationwide network of leading anatomic pathology laboratories. The partnership between AP2 and CombiMatrix begins effective immediately with UniPath, AP2's flagship laboratory based in Denver.
AP2 CEO Sami Abbasi notes that given AP2’s longstanding specialization in women's health, CMA testing for miscarriage analysis, also called Product of Conception (POC) testing, is a natural extension of AP2’s product offerings. “We are very pleased to be working with an advanced laboratory like CombiMatrix that specializes in CMA testing and has become a leader in the POC testing market. We believe this partnership will prove to be beneficial for both AP2's referring clinicians and their patients.”
CombiMatrix's POC test is the company's fastest-growing test in terms of volumes, notes Mark McDonough, CombiMatrix President and CEO. “Chromosomal microarray testing is proving to be a tremendously important tool in helping to identify the causes of miscarriages as well as assisting in future pregnancies,” McDonough says.”Working closely with AP2 will allow us to demonstrate the value and depth of our genetic diagnostic laboratory services in the markets where AP2 thrives.” Learn more about microarray analysis for miscarriages provided by CombiMatrix.
